INTRODUCTION: Enzalutamide is a novel antiandrogen which is approved for the treatment of metastatic, castration-resistant prostate cancer (mCRPC) after taxane-based chemotherapy. The efficacy of enzalutamide after the sequence docetaxel and abiraterone is not proven. METHODS: Thirty-five mCRPC patients in the German compassionate use program, who received enzalutamide after progression with taxane-based chemotherapy and abiraterone were prospectively evaluated. The endpoints of the study were overall survival, radiologic progression-free survival and safety. RESULTS: The median treatment duration on enzalutamide was 2.8 months. The median overall survival was 7.5 months [95% confidence interval (CI) 4.7-10.3] while median progression-free survival assessed by imaging was 3.1 months (95% CI 1.4-4.8). The most common toxicities of all grades were anemia and weight loss. CONCLUSION: Although the results are limited by a small patient number, the consecutive use of enzalutamide and abiraterone after taxane-based chemotherapy shows a modest clinical activity. Thus, sequence therapy alternating between chemotherapy and antihormonal drugs might be a more promising approach in mCRPC treatment.
INTRODUCTION:Enzalutamide is a novel antiandrogen which is approved for the treatment of metastatic, castration-resistant prostate cancer (mCRPC) after taxane-based chemotherapy. The efficacy of enzalutamide after the sequence docetaxel and abiraterone is not proven. METHODS: Thirty-five mCRPC patients in the German compassionate use program, who received enzalutamide after progression with taxane-based chemotherapy and abiraterone were prospectively evaluated. The endpoints of the study were overall survival, radiologic progression-free survival and safety. RESULTS: The median treatment duration on enzalutamide was 2.8 months. The median overall survival was 7.5 months [95% confidence interval (CI) 4.7-10.3] while median progression-free survival assessed by imaging was 3.1 months (95% CI 1.4-4.8). The most common toxicities of all grades were anemia and weight loss. CONCLUSION: Although the results are limited by a small patient number, the consecutive use of enzalutamide and abiraterone after taxane-based chemotherapy shows a modest clinical activity. Thus, sequence therapy alternating between chemotherapy and antihormonal drugs might be a more promising approach in mCRPC treatment.
Authors: Hung-Ming Lam; Ryan McMullin; Holly M Nguyen; Ilsa Coleman; Michael Gormley; Roman Gulati; Lisha G Brown; Sarah K Holt; Weimin Li; Deborah S Ricci; Karin Verstraeten; Shibu Thomas; Elahe A Mostaghel; Peter S Nelson; Robert L Vessella; Eva Corey Journal: Clin Cancer Res Date: 2016-12-19 Impact factor: 12.531
Authors: Eleni Efstathiou; Mark Titus; Sijin Wen; Anh Hoang; Maria Karlou; Robynne Ashe; Shi Ming Tu; Ana Aparicio; Patricia Troncoso; James Mohler; Christopher J Logothetis Journal: Eur Urol Date: 2014-05-29 Impact factor: 20.096
Authors: Heather Payne; Angus Robinson; Bernard Rappe; Serena Hilman; Ugo De Giorgi; Steven Joniau; Roberto Bordonaro; Stéphane Mallick; Louis-Marie Dourthe; Moisés Mira Flores; Josep Gumà; Benoit Baron; Aurea Duran; Alessandra Pranzo; Alexis Serikoff; David Mott; Mike Herdman; Marco Pavesi; Maria De Santis Journal: Int J Cancer Date: 2021-11-08 Impact factor: 7.316
Authors: H H Cheng; R Gulati; A Azad; R Nadal; P Twardowski; U N Vaishampayan; N Agarwal; E I Heath; S K Pal; H-T Rehman; A Leiter; J A Batten; R B Montgomery; M D Galsky; E S Antonarakis; K N Chi; E Y Yu Journal: Prostate Cancer Prostatic Dis Date: 2015-01-20 Impact factor: 5.554
Authors: Alejo Rodriguez-Vida; Myria Galazi; Sarah Rudman; Simon Chowdhury; Cora N Sternberg Journal: Drug Des Devel Ther Date: 2015-06-29 Impact factor: 4.162